Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers
- 31 March 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 9 (4), 492-499
- https://doi.org/10.1158/2159-8290.CD-18-1314
Abstract
Translational data on chimeric antigen receptor (CAR) T-cell trials indicate that the presence of naive T cells in the premanufacture product is important to clinical response and persistence. In anticipation of developing CAR trials for other tumors, we investigated the T-cell distribution from children with solid tumors and lymphomas at diagnosis and after every cycle of chemotherapy. We found that patients with T cells enriched for naive and stem central memory cells expanded well in vitro, but the majority of tumor types showed chemotherapy-related depletion of early lineage cells with a corresponding decline in successful ex vivo stimulation response. Unexpectedly, many pediatric patients with solid tumors had low numbers of naive T cells prior to any therapy. These data indicate the ex vivo manufacture of CART cells may need to be customized based on the nature of T cells available in each disease type. SIGNIFICANCE: Cumulative chemotherapy cycles deplete naive T cells in many pediatric cancer regimens, reducing expansion potential associated with successful adoptive cellular therapies. Naive T-cell deficits can be seen at diagnosis as well, implying immune deficits that exist prior to chemotherapy, which may also affect the development of immune-based therapies.Keywords
Other Versions
Funding Information
- St. Baldrick's Foundation ()
- Doris Duke Charitable FoundationJeffrey Pride Foundation ()
- SU2C ()
This publication has 27 references indexed in Scilit:
- Cellular immunotherapy for pediatric solid tumorsCytotherapy, 2014
- Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapyCytotherapy, 2014
- Chimeric Antigen Receptor Therapy for CancerAnnual Review of Medicine, 2014
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Autologous and Allogeneic Cellular Therapies for High-risk Pediatric Solid TumorsPediatric Clinics of North America, 2010
- Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemiaBlood, 2005
- Lymphocyte subsets in healthy children from birth through 18 years of age: The pediatric AIDS clinical trials group P1009 studyJournal of Allergy and Clinical Immunology, 2003
- Cellular immunosuppression in children with acute lymphoblastic leukemia: Effect of consolidation chemotherapyCancer Immunology, Immunotherapy, 1992
- Long term effects of radiation of T and B lymphocytes in peripheral blood of patients with Hodgkin's disease.JCI Insight, 1976